Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $14.2050 (-2.81%) ($14.1500 - $14.6800) on Wed. Aug. 26, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.7% (three month average) | RSI | 33 | Latest Price | $14.2050(-2.81%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.8% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.7% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) IWO(51%) XBI(50%) IWM(47%) IWC(45%) | Factors Impacting FOLD price | FOLD will decline at least -1.85% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-12%) UNG(-4%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.85% (StdDev 3.7%) | Hourly BBV | -1.4 () | Intraday Trend | 0% | | | |
|
Resistance Level | $14.74 | 5 Day Moving Average | $14.49(-1.97%) | 10 Day Moving Average | $14.59(-2.64%) | 20 Day Moving Average | $14.74(-3.63%) | To recent high | -10.6% | To recent low | 30% | Market Cap | $3.668b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |